B6.Cg-Tg(Tagln-PLA2G2A*G29S)AMrj/Orl
| Status | Available to order |
| EMMA ID | EM:07419 |
| Citation information | RRID:IMSR_EM:07419 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | B6.Cg-Tg(Tagln-PLA2G2A*G29S)AMrj/Orl |
| Alternative name | SM22a-humansPLA2IIA MA |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(Tagln-PLA2G2A*G29S)AMrj |
| Gene/Transgene symbol | Tg(Tagln-PLA2G2A*G29S)AMrj |
Information from provider
| Provider | Michel Raymondjean |
| Provider affiliation | UR4 , University Pierre et Marie Curie (Paris VI) |
| Genetic information | Group IIA sPLA2 (PLA2, EC 3.1.1.4), also known as synovial sPLA2, is an acute reactant up regulated during numerous inflammatory processes both in local and systemic inflammatory conditions. We demonstrated that sPLA2 IIA has paracrine/autocrine functions in vascular smooth muscle cells (Jaulmes et al Arterioscler Thromb Vasc Biol 2004; 25:1161-7), even if catalitically inactive. The human sPLA2-V5-His HindIII/XbaI fragment, encompassing the mutation in the catalytic site (G29S), and the conserved interacting properties to proteoglycans, was inserted into the pBluescript II KS downstream part of SM22a gene (Tagln1), from -2126bp to +4136bp, obtained from Moessler et al (Development 1996, 122:2415-25). The construct comprises promoter, first exon, first intron and part of exon 2 (11bp) of SM22a gene. Tg mice were produced by standard methods. After digest by BssHII of the plasmid containing the construct, the 7.2kb fragment was injected into the pronuclei of B6D2 fertilized oocytes. |
| Phenotypic information | Copy number was estimated to be over 50 by genomic Southern blotting of mouse tail DNA. Expression of sPLA2mRNA in various tissues (liver, lung, skeletal muscle, heart and aorta) was assessed by PCR and visualized by Western blotting in the homogenates of these tissues. As expected, the expression of human sPLA2IIA was found in tissues enriched in smooth muscle cells as aorta, lung and heart. The tissue specific expression driven by the SM22a promoter was verified. Since C57BL/6 mice share a frameshift mutation in the exon 3 of the endogenous Pla2g2a gene, these animal models of sPLA2-IIA tissue-specific expression may provide a new approach for better understanding its impact in the initiation and progression of vascular diseases and may allow the development of more specific new inhibitors in the context of systemic inflammation. |
| Breeding history | SM22a-sPLA2 IIA F0 mice were backcrossed repeatedly four times with C57BL/6 mice (from Charles River) which are natural knockouts for mouse sPLA2 (Kramer et al J. Biol. Chem1995, 270: 22378-22385). Then we have preserved only two independent lines of mutated (MA and MB) transgenic mice. The animals were backcrossed on a C57BL/6 (n>12) genetic background. All experiments involving mice were approved by the Institutional Committee (agreement n.5876). |
| References | None available |
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | CNRS-TAAM – Typing and Archiving of Animal Models, Orléans, France |
| Animals used for archiving | homozygous C57BL/6J males |